Total Payments
$200,483
2024 Payments
$43,135
Companies
12
Transactions
70
Medicare Patients
1,120
Medicare Billing
$68,973
Payment Breakdown by Category
Consulting$190,153 (94.8%)
Travel$5,240 (2.6%)
Research$2,700 (1.3%)
Food & Beverage$1,269 (0.6%)
Other$1,121 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $190,153 | 35 | 94.8% |
| Travel and Lodging | $5,240 | 14 | 2.6% |
| Unspecified | $2,700 | 2 | 1.3% |
| Food and Beverage | $1,269 | 17 | 0.6% |
| Honoraria | $750.00 | 1 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $371.18 | 1 | 0.2% |
Payments by Type
General
$197,783
68 transactions
Research
$2,700
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Chugai Pharmaceutical Co., Ltd. | $97,293 | 22 | $0 (2024) |
| GENZYME CORPORATION | $32,035 | 14 | $0 (2023) |
| GlaxoSmithKline, LLC. | $23,016 | 7 | $0 (2022) |
| SANOFI US SERVICES INC. | $15,244 | 3 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $11,982 | 7 | $0 (2023) |
| UCB SA | $7,150 | 8 | $0 (2019) |
| Janssen Research & Development, LLC | $6,250 | 1 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $3,375 | 1 | $0 (2022) |
| Amgen Inc. | $2,100 | 2 | $0 (2019) |
| Covidien LP | $787.90 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $43,135 | 8 | Chugai Pharmaceutical Co., Ltd. ($33,247) |
| 2023 | $54,996 | 24 | GENZYME CORPORATION ($32,035) |
| 2022 | $47,642 | 14 | Chugai Pharmaceutical Co., Ltd. ($23,451) |
| 2021 | $26,625 | 3 | Chugai Pharmaceutical Co., Ltd. ($20,125) |
| 2020 | $15,650 | 4 | Takeda Pharmaceuticals U.S.A., Inc. ($7,150) |
| 2019 | $6,197 | 5 | UCB SA ($2,300) |
| 2018 | $600.27 | 2 | Eli Lilly and Company ($500.00) |
| 2017 | $5,637 | 10 | UCB SA ($4,850) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | Chugai Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $116.67 | General |
| 10/01/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $13,685.00 | General |
| 08/26/2024 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $4,944.00 | General |
| 07/01/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $4,025.00 | General |
| 05/17/2024 | Chugai Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $125.43 | General |
| 04/01/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $6,842.50 | General |
| 02/02/2024 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $4,944.00 | General |
| 01/15/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $8,452.50 | General |
| 10/16/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $33.94 | General |
| 10/15/2023 | Chugai Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $82.69 | General |
| 10/01/2023 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $3,220.00 | General |
| 09/06/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $14,008.00 | General |
| Category: Immunology | ||||||
| 09/06/2023 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $14,008.00 | General |
| 09/06/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $803.75 | General |
| Category: Immunology | ||||||
| 09/06/2023 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $803.75 | General |
| 09/06/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $559.38 | General |
| Category: Immunology | ||||||
| 09/06/2023 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $559.38 | General |
| 09/06/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $391.40 | General |
| Category: Immunology | ||||||
| 09/06/2023 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $391.40 | General |
| 09/06/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $163.71 | General |
| 09/06/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $99.89 | General |
| Category: Immunology | ||||||
| 09/06/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $91.20 | General |
| Category: Immunology | ||||||
| 09/06/2023 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $91.20 | General |
| 09/06/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $52.72 | General |
| Category: Immunology | ||||||
| 09/06/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $11.10 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF IMMUNE ACTIVATION AND TOLERANCE IN CELIAC DISEASE DURING GLUTEN CHALLENGE | Takeda Pharmaceuticals U.S.A., Inc. | $2,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 123 | 127 | $34,752 | $7,210 |
| 2022 | 12 | 302 | 312 | $118,303 | $18,015 |
| 2021 | 14 | 328 | 345 | $31,789 | $22,129 |
| 2020 | 14 | 367 | 377 | $31,446 | $21,620 |
Total Patients
1,120
Total Services
1,161
Medicare Billing
$68,973
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 25 | $7,250 | $2,433 | 33.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 31 | 35 | $6,615 | $2,366 | 35.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,876 | $1,011 | 26.1% |
| 91037 | Monitoring and recording of esophageal function through nasal tube with electrode | Facility | 2023 | 22 | 22 | $8,888 | $844.36 | 9.5% |
| 91034 | Monitoring and recording of esophageal function through nasal tube | Facility | 2023 | 14 | 14 | $5,824 | $504.66 | 8.7% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 19 | 19 | $2,299 | $50.63 | 2.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 41 | 42 | $12,340 | $4,115 | 33.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 46 | 49 | $9,582 | $3,230 | 33.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 12 | 12 | $20,790 | $2,257 | 10.9% |
| 91010 | Study of esophagus to assess movement | Facility | 2022 | 36 | 36 | $17,856 | $1,732 | 9.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 12 | 12 | $23,448 | $1,362 | 5.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 16 | 16 | $5,567 | $1,190 | 21.4% |
| 91037 | Monitoring and recording of esophageal function through nasal tube with electrode | Facility | 2022 | 27 | 27 | $10,530 | $1,031 | 9.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 13 | 13 | $1,625 | $943.37 | 58.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 28 | 34 | $1,602 | $801.02 | 50.0% |
| 91034 | Monitoring and recording of esophageal function through nasal tube | Facility | 2022 | 18 | 18 | $7,236 | $650.90 | 9.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 13 | 13 | $1,906 | $566.09 | 29.7% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2022 | 40 | 40 | $5,821 | $135.84 | 2.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 44 | 54 | $4,902 | $3,974 | 81.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 32 | 34 | $4,702 | $3,243 | 69.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 14 | $2,512 | $1,988 | 79.1% |
| 91010 | Measurement of esophageal swallowing movement | Facility | 2021 | 38 | 38 | $2,892 | $1,850 | 64.0% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 18 | 18 | $3,585 | $1,809 | 50.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $2,154 | $1,680 | 78.0% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 12 | 12 | $2,385 | $1,629 | 68.3% |
About Dr. Joseph Murray, M.D
Dr. Joseph Murray, M.D is a Gastroenterology healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538149018.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Murray, M.D has received a total of $200,483 in payments from pharmaceutical and medical device companies, with $43,135 received in 2024. These payments were reported across 70 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($190,153).
As a Medicare-enrolled provider, Murray has provided services to 1,120 Medicare beneficiaries, totaling 1,161 services with total Medicare billing of $68,973. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Rochester, MN
- Active Since 01/19/2006
- Last Updated 08/19/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1538149018
Products in Payments
- DUPIXENT (Biological) $16,017
- Non-Covered Product (Drug) $3,026
- Cimzia (Drug) $2,300
- Barrx (Device) $787.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Rochester
Edward Loftus, M.d, M.D
Gastroenterology — Payments: $379,661
Gastroenterology $379,661
Christopher Gostout, M.d, M.D
Gastroenterology — Payments: $317,848
Gastroenterology $317,848
Vivek Kaul, Md, MD
Gastroenterology — Payments: $307,068
Gastroenterology $307,068
Todd Baron, M.d, M.D
Gastroenterology — Payments: $296,029
Gastroenterology $296,029
Russell Wiesner, M.d, M.D
Gastroenterology — Payments: $231,350
Gastroenterology $231,350
Ibrahim Hanouneh, M.d, M.D
Gastroenterology — Payments: $152,486
Gastroenterology $152,486